Literature DB >> 20332638

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.

M Degerman Gunnarsson1, M Lindau, A Wall, K Blennow, T Darreh-Shori, S Basu, A Nordberg, A Larsson, L Lannfelt, H Basun, L Kilander.   

Abstract

BACKGROUND: The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PIB) is an in vivo ligand for measuring beta-amyloid (Abeta) load. Associations between PET PIB and cerebrospinal fluid (CSF) Abeta1-42 and apolipoprotein E epsilon4 (APOE epsilon4) have been observed in several studies, but the relations between PIB uptake and other biomarkers of Alzheimer's disease (AD) are less investigated.
METHOD: PET PIB, PET 18Fluoro-2-deoxy-D-glucose and different AD biomarkers were measured twice in CSF, plasma and urine 12 months apart in 10 patients with a clinical diagnosis of mild to moderate AD.
RESULTS: PIB retention was constant over 1 year, inversely related to low CSF Abeta1-42 (p = 0.01) and correlated positively to the numbers of the APOE epsilon4 allele (0, 1 or 2) (p = 0.02). There was a relation between mean PIB retention and CSF ApoE protein (r = -0.59, p = 0.07), and plasma cystatin C (r = -0.56, p = 0.09).
CONCLUSION: PIB retention is strongly related to CSF Abeta1-42, and to the numbers of the APOE epsilon4 allele. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332638     DOI: 10.1159/000281832

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  18 in total

1.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

2.  Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.

Authors:  Stephen D Weigand; Prashanthi Vemuri; Heather J Wiste; Matthew L Senjem; Vernon S Pankratz; Paul S Aisen; Michael W Weiner; Ronald C Petersen; Leslie M Shaw; John Q Trojanowski; David S Knopman; Clifford R Jack
Journal:  Alzheimers Dement       Date:  2011-02-01       Impact factor: 21.566

3.  Evidence for ordering of Alzheimer disease biomarkers.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Paul S Aisen; John Q Trojanowski; Leslie M Shaw; Matthew A Bernstein; Ronald C Petersen; Michael W Weiner; David S Knopman
Journal:  Arch Neurol       Date:  2011-08-08

4.  Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.

Authors:  D P Devanand; N Schupf; Y Stern; R Parsey; G H Pelton; P Mehta; R Mayeux
Journal:  Neurology       Date:  2011-06-29       Impact factor: 9.910

5.  Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study.

Authors:  Audrey Gabelle; Florence Richard; Laure-Anne Gutierrez; Susanna Schraen; Fleur Delva; Olivier Rouaud; Luc Buée; Jean-François Dartigues; Jacques Touchon; Jean-Charles Lambert; Claudine Berr
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328.

Authors:  Scott T Harrison; James Mulhearn; Scott E Wolkenberg; Patricia J Miller; Stacey S O'Malley; Zhizhen Zeng; David L Williams; Eric D Hostetler; Sandra Sanabria-Bohórquez; Linda Gammage; Hong Fan; Cyrille Sur; J Christopher Culberson; Richard J Hargreaves; Jacquelynn J Cook; George D Hartman; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2011-04-18       Impact factor: 4.345

Review 7.  Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel; Henrik Zetterberg
Journal:  Neuropsychopharmacology       Date:  2013-06-25       Impact factor: 7.853

Review 8.  In vivo human amyloid imaging.

Authors:  J Sojkova; S M Resnick
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

9.  Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition.

Authors:  Stephanie A Schultz; Elizabeth A Boots; Rodrigo P Almeida; Jennifer M Oh; Jean Einerson; Claudia E Korcarz; Dorothy F Edwards; Rebecca L Koscik; Maritza N Dowling; Catherine L Gallagher; Barbara B Bendlin; Bradley T Christian; Henrik Zetterberg; Kaj Blennow; Cynthia M Carlsson; Sanjay Asthana; Bruce P Hermann; Mark A Sager; Sterling C Johnson; James H Stein; Ozioma C Okonkwo
Journal:  J Int Neuropsychol Soc       Date:  2015-11       Impact factor: 2.892

10.  Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.

Authors:  Agneta Nordberg
Journal:  Alzheimers Res Ther       Date:  2011-12-02       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.